Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095511 | 0.98 | TGFBR1 (0.37) | TGFBR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24298651 | 0.87 | TGFBR1 (0.39) | TGFBR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24299179 | 0.85 | TGFBR1 (0.39) | TGFBR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24095432 | 0.84 | PSEN1 (0.35) | TGFBR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24095393 | 0.81 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL24095395 | 0.79 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL24095512 | 0.79 | TGFBR1 (0.42) | TGFBR1PDE4DCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL24095470 | 0.73 | TGFBR1 (0.59) | TGFBR1PDE4D | |
| SCHEMBL24095510 | 0.73 | TGFBR1 (0.59) | TGFBR1 | |
| SCHEMBL24095460 | 0.72 | TGFBR1 (0.52) | TGFBR1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3922631-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. (CN) | 2021-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885PSEN1 1927/4885PSEN2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.